Review of regulation of biological and biotechnological products in Latin American and Caribbean countries

Biologicals

Volumn 37, Issue 5, 2009, Pages 271-276

  Pombo, María L ^a   Di Fabio, José L ^a   Cortés, María de los A ^a  

^a PAN AMERICAN HEALTH ORGANIZATION   (United States)

Author keywords

Biological products; Biosimilars; Biotech products; Biotechnological products; Regulation

Indexed keywords

BIOLOGICAL PRODUCT; BLOOD CLOTTING FACTOR; BLOOD DERIVATIVE; ENOXAPARIN; HUMAN ALBUMIN; IMMUNOGLOBULIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HUMAN INSULIN; STREPTOKINASE; UROKINASE; VACCINE;

BIOTECHNOLOGICAL PRODUCTION; BIOTECHNOLOGY; CENTRAL AMERICA; DRUG APPROVAL; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; SOUTH AND CENTRAL AMERICA;

BIOLOGICAL PRODUCTS; BIOMEDICAL RESEARCH; BIOTECHNOLOGY; CARIBBEAN REGION; DATA COLLECTION; HEALTH POLICY; HEALTH SERVICES RESEARCH; HUMANS; LATIN AMERICA; PAN AMERICAN HEALTH ORGANIZATION;

EID: 69649092025     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2009.07.003     Document Type: Review

References (30)

1. World Health Organization. Training manual: licensing, lot release, laboratory access; 2001.
2. World Health Organization. Annex 1: good manufacturing practices for biological products. Geneva: WHO; 1992. Technical Report Series: 822.
3. World Health Organization [Homepage]. Geneva: The Organization; 2008 [cited on February 10th 2008]. Biologicals, Available from: http://who.int/biologicals/areas/en.
4. World Health Organization. Annex 2: guidelines for national authorities on quality assurance for biological products. Geneva: WHO; 1992. Technical Report Series: 822.
5. Organización Panamericana de la Salud. Módulos I y II: Vacunas de Calidad, Washington: OPS; 2004.
6. World Health Organization. Annex 3: guidelines for assuring the quality of pharmaceutical and biological products prepared by recombinant DNA technology. Geneva: WHO; 1991. Technical Report Series: 814.
7. World Health Organization. Annex 3: requirements for human interferons prepared from lymphoblastoid cells. Geneva: WHO; 1989. Technical Report Series: 786.
8. World Health Organization. Annex 7: requirements for human interferons made by recombinant DNA techniques. Geneva: WHO; 1988. Technical Report Series: 771.
9. World Health Organization. Annex 3: guidelines for assuring the quality of monoclonal antibodies for use in humans. Geneva: WHO; 1992. Technical Report Series: 822. Monoclonal antibodies.
10. World Health Organization. WHO Informal Consultation on International Nonproprietary Names (INN) Policy for Biosimilar Products. Geneva; September 2006.
11. World Health Organization. Meeting report of WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products; 2007.
12. World Health Organization. WHO International biological reference preparations held and distributed by the WHO International laboratories for biological standards cytokines/growth factors http://www.who.int/bloodproducts/catalogue/en/index.html; 2007.
13. European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04; 2005.
14. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. EMEA/CHMP/BWP/49348/2005.
15. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005.
16. European Medicines Agency. Concept paper on similar biological medicinal products containing low molecular weight heparins-non-clinical issues. EMEA/CHMP/BMWP/496286/2006.
17. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. EMEA/CHMP/BMWP/31329/2005.
18. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant human soluble insulin. EMEA/CHMP/BMWP/32775/2005.
19. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant erythropoietin. EMEA/CHMP/BMWP/94526/2005.
20. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing somatropin. EMEA/CHMP/BMWP/94528/2005.
21. European Medicines Agency. Guideline on comparability of biotechnology-derived therapeutic products after a change in the manufacturing process. Non-clinical and clinical issues. EMEA/CHMP/BMPW/101695/2006.
22. European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006.
23. European Medicines Agency. Guidance on comparability of medicinal products containing biotechnology-derived proteins as active substance. Non-clinical and clinical issues. EMEA/CPMP/3097/02/2003.
24. European Medicines Agency. Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: quality issues. EMEA/CPMP/BWP/3207/00/2003.
25. International Conference on Harmonization of Technical Requirements for registration of pharmaceuticals for human use. Comparability of biotechnological/biological products subject to changes in their manufacturing process Q5E; 2004.
26. International Conference on Harmonization of Technical Requirements for registration of pharmaceuticals for human use. Quality of biotechnological products: stability testing of biotechnological/biological products Q5C; 1995.
27. International Conference on Harmonization of Technical Requirements for registration of pharmaceuticals for human use. Specifications: Test procedures and acceptance criteria for biotechnological/biological products Q6B; 1999.
28. International Conference on Harmonization of Technical Requirements for registration of pharmaceuticals for human use. Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6; 1997.
29. ICDRA. 12th International Conference of Drug Regulatory Authorities, Recommendations http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/recc_final; 2006.
30. Cortés M., and Di Fabio J. Regulation of small-molecule drugs versus biologicals versus biotech products. In: Gad S.C. (Ed). Handbook of pharmaceutical biotechnology (2007) 1373-1390